Expert Rev Cardiovasc Ther. 2010 Mar;8(3):339-43
Authors: Grant RW, Wexler DJ
Continuing advances in genetic discovery have uncovered several dozen loci that are associated with Type 2 diabetes, including genetic variants that appear to modify responses to commonly prescribed diabetes medications. The use of an individual's genetic information to guide therapy choices raises the possibility of 'personalized medicine', wherein each patient's treatment plan is tailored based on genotype results. However, before such a model of care can be implemented, research is needed to more clearly quantify the association of genetic variation with treatment outcomes and adverse effects. In this article, we review a study examining the association of genetic variation in the cytochrome P450 2C9 enzyme with glycemic response to sulfonylureas in a large cohort of patients with Type 2 diabetes from the Genetics of Diabetes Audit and Research Tayside Study (Go-DARTS).
PMID: 20222813 [PubMed - indexed for MEDLINE]